Normal view MARC view ISBD view

Breast Cancer and Heart Failure. [Review]

MedStar author(s):

Citation: Heart Failure Clinics. 15(1):65-75, 2019 Jan.PMID: 30449381Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antineoplastic Agents | *Breast Neoplasms/th [Therapy] | *Heart Failure | *Patient Care Management/mt [Methods] | Antineoplastic Agents/ae [Adverse Effects] | Antineoplastic Agents/tu [Therapeutic Use] | Cardiotoxicity/et [Etiology] | Cardiotoxicity/pc [Prevention & Control] | Female | Heart Failure/ci [Chemically Induced] | Heart Failure/pc [Prevention & Control] | Humans | Trastuzumab/ae [Adverse Effects] | Trastuzumab/tu [Therapeutic Use] | Ventricular Dysfunction, Left/pp [Physiopathology]Year: 2019 ISSN:

1551-7136

Name of journal: Heart failure clinicsAbstract: Copyright (c) 2018 Elsevier Inc. All rights reserved.Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after cancer treatment are of utmost importance. This review presents advances, challenges, and opportunities for cardiovascular care in contemporary breast cancer treatment.All authors: Almuwaqqat Z, Barac A, Meisel JL, Parashar SFiscal year: FY2019Digital Object Identifier:

https://dx.doi.org/10.1016/j.hfc.2018.08.007

Date added to catalog: 2018-12-14

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	30449381	Available		30449381

Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Early recognition and management of cardiovascular risk factors before, during, and after cancer treatment are of utmost importance. This review presents advances, challenges, and opportunities for cardiovascular care in contemporary breast cancer treatment.

English